Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Glioma 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Analgesia 7Psychiatric Rehabilitation 3Docetaxel 3Morphine 2Acupuncture Therapy 2valdecoxib 1tandutinib 1Therapeutics 1Radiotherapy 1Pharmacogenomic Testing 1Oxycodone 1Musculoskeletal Manipulations 1Massage 1Levopropoxyphene 1Ketamine 1Ibandronic Acid 1Gelclair 1Filgrastim 1Early Intervention, Educational 1Doxorubicin 1Cyclophosphamide 1Codeine 1Aromatherapy 1Animal Assisted Therapy 1Acetaminophen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pain × tandutinib × Clear all
NCT00390468 2014-05-28

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 5 charts
Genitourinary

Neoplasm Metastasis, Pain, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡